{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H2+receptor+antagonist&page=2", "query": { "intervention": "H2 receptor antagonist", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 63, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H2+receptor+antagonist&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H2+receptor+antagonist&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T03:12:38.499Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07216703", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1023, "start_date": "2026-01-19", "completion_date": "2031-10-29", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Irvine, California • Orange, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216703" }, { "nct_id": "NCT06074588", "title": "Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 556, "start_date": "2023-11-12", "completion_date": "2030-03-11", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 16, "location_summary": "Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06074588" }, { "nct_id": "NCT06637423", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2024-12-20", "completion_date": "2029-03-14", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 4, "location_summary": "Bakersfield, California • Tampa, Florida • Chicago, Illinois + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06637423" }, { "nct_id": "NCT06428409", "title": "A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin (LV) or levoleucovorin", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2024-06-20", "completion_date": "2029-10-16", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 13, "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428409" }, { "nct_id": "NCT02375204", "title": "Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Germ Cell Tumor", "Teratoma", "Choriocarcinoma", "Germinoma", "Mixed Germ Cell Tumor", "Yolk Sac Tumor", "Childhood Teratoma", "Malignant Germ Cell Neoplasm", "Extragonadal Seminoma", "Non-seminomatous Germ Cell Tumor", "Seminoma" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "pegylated G-CSF", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "stem cell reinfusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "MALE", "summary": "14 Years and older · Male only" }, "enrollment_count": 420, "start_date": "2015-08-06", "completion_date": "2031-06-01", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 77, "location_summary": "Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02375204" }, { "nct_id": "NCT00972205", "title": "Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical", "Ovarian", "Lung", "Breast", "Renal" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "CBT-1(Registered Trademark)", "type": "DRUG" }, { "name": "Tc 99m sestamibi", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 12, "start_date": "2007-12", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2012-07-19", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00972205" }, { "nct_id": "NCT04990388", "title": "Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glycogen Storage Disease Type III" ], "interventions": [ { "name": "UX053", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Antipyretic", "type": "DRUG" }, { "name": "H2 Blocker", "type": "DRUG" }, { "name": "H1 Blocker", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Ultragenyx Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2021-10-18", "completion_date": "2023-03-20", "has_results": true, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 4, "location_summary": "Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990388" }, { "nct_id": "NCT03541408", "title": "Preventative Delirium Protocol in Elderly Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Delirium" ], "interventions": [ { "name": "Control", "type": "OTHER" }, { "name": "Preventative Delirium Protocol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "65 Years to 89 Years" }, "enrollment_count": 263, "start_date": "2016-05-01", "completion_date": "2021-04-01", "has_results": false, "last_update_posted_date": "2022-12-12", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03541408" }, { "nct_id": "NCT02906670", "title": "Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology" ], "interventions": [ { "name": "Sym013", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-11-01", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2020-08-28", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 3, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02906670" }, { "nct_id": "NCT06460961", "title": "A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis" ], "interventions": [ { "name": "MK-6837", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-07-14", "completion_date": "2026-07-29", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-01T03:12:38.499Z", "location_count": 3, "location_summary": "Morristown, New Jersey • Portland, Oregon • San Antonio, Texas", "locations": [ { "city": "Morristown", "state": "New Jersey" }, { "city": "Portland", "state": "Oregon" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06460961" } ] }